research Small Molecule Wnt Pathway Inhibitor (SM04755) as a Potential Topical Psoriasis Treatment
SM04755 may be an effective topical treatment for psoriasis.
Search
for
Sort by
Research
30 / 1000+ results research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research A Small Molecule Inhibitor Partitions Two Distinct Pathways for Trafficking of Tonoplast Intrinsic Proteins in Arabidopsis
Two distinct pathways direct proteins to vacuoles in Arabidopsis, affecting root hair growth and protein targeting.
research Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
research HaCaT-Conditioned Medium Supplemented with Small Molecule Inhibitors SB431542 and CHIR99021 and Growth Factor PDGF-AA Prevents the Dedifferentiation of Dermal Papilla Cells In Vitro
A mix of specific inhibitors and a growth factor helps keep hair growth cells from losing their properties in the lab.
research Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
The treatment was ineffective in humans.
research The Emerging Role of Janus Kinase Inhibitors in the Treatment of Autoimmune and Inflammatory Diseases
Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
research Molecular Targeted Agents and Biologic Therapies for Non-Small Cell Lung Cancer
New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
research Targeting the Wnt Pathways for Therapies
Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.
research The Roles of Wnt/β-Catenin Pathway in Tissue Development and Regenerative Medicine
The Wnt/β-catenin pathway is important for tissue development and has potential in regenerative medicine, but requires more research for therapeutic use.
research Wnt Signaling Activation: Targets and Therapeutic Opportunities for Stem Cell Therapy and Regenerative Medicine
Wnt activation shows promise for regenerative medicine but requires selective targeting to minimize risks like cancer.
research Hair Growth Induced by Blockade of Macrophage-Derived Oncostatin M and Downstream JAK-STAT5 Signaling in Hair Follicle Stem Cells
Blocking a specific immune cell signal can trigger hair growth.
research Wnt/β-Catenin Pathway in Tissue Injury: Roles in Pathology and Therapeutic Opportunities for Regeneration
The Wnt/β-catenin pathway helps tissue regeneration but can also cause fibrosis, and drugs that inhibit this pathway may aid in healing skin and heart tissues.
research Chemotherapy-Induced Iatrogenic Injury of Skin: New Drugs and New Concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
research Conditional Ablation of JAK-STAT5 Signaling Induces Anagen Hair Growth
Blocking JAK-STAT5 signaling in mice leads to hair growth.
research Colon Cancer Stem Cells: Promise of Targeted Therapy
Targeting colon cancer stem cells might lead to better treatment results.
research Modulation of YBX1 Phosphorylation Determines Epidermal Stem Cell Function
Changing YBX1 protein activity affects skin stem cell function and aging.
research Small Molecules and Small Molecule Drugs in Regenerative Medicine
Small molecule drugs show promise for advancing regenerative medicine but still face development challenges.
research Small Molecule Wnt Pathway Modulators from Natural Sources: History, State of the Art and Perspectives
Natural small molecules can help treat diseases by activating or inhibiting the Wnt pathway.
research The Use of Phosphodiesterase Inhibitors for the Treatment of Alopecia
Caffeine shows promise for treating some types of hair loss, but more research is needed.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Spatiotemporal Control of CRISPR/Cas9 Gene Editing
The document concludes that while there are promising methods to control CRISPR/Cas9 gene editing, more research is needed to overcome challenges related to safety and effectiveness for clinical use.
research New Developments in the Molecular Treatment of Ichthyosis: Review of the Literature
New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.
research IL-36γ Drives Skin Toxicity Induced by EGFR/MEK Inhibition and Commensal Cutibacterium Acnes
A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
research Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
research Identifying Novel Strategies for Treating Human Hair Loss Disorders: Cyclosporine A Suppresses the Wnt Inhibitor, SFRP1, in the Dermal Papilla of Human Scalp Hair Follicles
Cyclosporine A may help treat hair loss by blocking a protein that inhibits hair growth.
research Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
A blood pressure drug, diltiazem, may also help treat influenza.
research Multicentric Parallel Phase II Trial of the Polo-Like Kinase 1 Inhibitor BI 2536 in Patients With Advanced Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, and Melanoma. The First Protocol of the European Organization for Research and Treatment of Cancer Network of Core Institutes
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.